...
首页> 外文期刊>Informatics in Medicine Unlocked >Computational prediction of potential siRNA and human miRNA sequences to silence orf1ab associated genes for future therapeutics against SARS-CoV-2
【24h】

Computational prediction of potential siRNA and human miRNA sequences to silence orf1ab associated genes for future therapeutics against SARS-CoV-2

机译:沉默疗法的潜在siRNA和人体miRNA序列的计算预测未来治疗对抗SARS-COV-2的疗效基因

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The coronavirus disease 2019 (COVID-19) is an ongoing pandemic caused by an RNA virus termed as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). SARS-CoV-2 possesses an almost 30kbp long genome. The genome contains open-reading frame 1ab (ORF1ab) gene, the largest one of SARS-CoV-2, encoding polyprotein PP1ab and PP1a responsible for viral transcription and replication. Several vaccines have already been approved by the respective authorities over the world to develop herd immunity among the population. In consonance with this effort, RNA interference (RNAi) technology holds the possibility to strengthen the fight against this virus. Here, we have implemented a computational approach to predict potential short interfering RNAs including small interfering RNAs (siRNAs) and microRNAs (miRNAs), which are presumed to be intrinsically active against SARS-CoV-2. In doing so, we have screened miRNA library and siRNA library targeting the ORF1ab gene. We predicted the potential miRNA and siRNA candidate molecules utilizing an array of bioinformatic tools. By extending the analysis, out of 24 potential pre-miRNA hairpins and 131 siRNAs, 12 human miRNA and 10 siRNA molecules were sorted as potential therapeutic agents against SARS-CoV-2 based on their GC content, melting temperature (Tm), heat capacity (Cp), hybridization and minimal free energy (MFE) of hybridization. This computational study is focused on lessening the extensive time and labor needed in conventional trial and error based wet lab methods and it has the potential to act as a decent base for future researchers to develop a successful RNAi therapeutic.
机译:Coronavirus疾病2019(Covid-19)是由RNA病毒称为严重急性呼吸综合征Coronavirus-2(SARS-COV-2)所引起的持续流行病。 SARS-COV-2具有近30kbp的基因组。该基因组含有开放读数框1ab(ORF1ab)基因,SARS-COV-2中最大的一种,编码PP1ab和负责病毒转录和复制的PP1A。几个疫苗已经被世界各国批准的世界批准,以发展人口之间的畜牧业。在与此努力的合作中,RNA干扰(RNAi)技术能够加强对抗这种病毒的斗争。在这里,我们已经实施了计算方法来预测包括小干扰RNA(siRNA)和Micrornas(MiRNA)的潜在短干扰RNA,其被推测为本质上对抗SARS-COV-2。在这样做时,我们已经筛选了靶向orf1ab基因的miRNA文库和siRNA文库。我们预测利用一系列生物信息工具的潜在miRNA和siRNA候选分子。通过延长分析,除了24个潜在的前miRNA发夹和131个SiRNA,12个人miRNA和10 siRNA分子基于GC含量,熔化温度(TM),热容量,对SARS-COV-2的潜在治疗剂分类为潜在的治疗剂(CP),杂交和最小自由能(MFE)的杂交。该计算研究专注于减少传统试验和基于误差的湿式实验方法所需的广泛时间和劳动,并且它有可能作为未来研究人员开发成功的RNAi治疗的体面基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号